Related Experiment Video

Updated: Jul 10, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

7.7K

A 30-minute intravenous infusion of rituximab is safe and cost-effective (SpeedR)

Björn Engelbrekt Wahlin1,2, Maria Ljungqvist3,4, Ola Falk4

  • 1Division of Hematology, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. bjorn.wahlin@gmail.com.

Annals of Hematology
|July 31, 2025
PubMed

Rituximab is a monoclonal antibody used in the treatment of B-cell malignancies. Infusion reactions are common during the first exposure but decrease with subsequent infusions. We here present our experience with a protocol for a 30-minute intravenous infusion of rituximab (SpeedR) to patients who have previously tolerated a 90-minute rituximab infusion. All patients were premedicated with 10 mg cetirizine and 1 g paracetamol (steroids were only given when part of a concomitant chemotherapy regimen). In this cohort 268 patients received a total of 940 intravenous 30-minute infusions with only nine patients having adverse reactions (all grade 1-2) which required little or no treatment. Out of the nine patients with reactions, seven were planned for more rituximab treatment and all of them could later continue with 30-minute rituximab infusions. We conclude that 30-minute rituximab infusions are a safe and efficient way to optimize workflow in the outpatient clinic and to give cost-effective treatment to lymphoma patients.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.8K

Related Concept Videos

Routes of Drug Administration: Parenteral01:25

Routes of Drug Administration: Parenteral

The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...